The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Influence of Voluntary Isocapnic Hyperpnea on Blood Lactate Level and Rate of Perceived Exertion

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05994092
Recruitment Status : Completed
First Posted : August 16, 2023
Last Update Posted : August 18, 2023
Sponsor:
Information provided by (Responsible Party):
Tomasz Kowalski, Institute of Sport - National Research Institute, Poland

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
All the study participants performed the Wingate Anaerobic Test (WAnT) with maximal effort. The experimental group (E) performed a 3-minute recovery protocol based on low-intensity breathing Voluntary Isocapnic Hyperpnea exercises 20 minuter after cessation of the exercise, whereas the control group (C) used passive recovery only. All study participants were advised to sit during the 30-minute period, with minimal walking in order to meet the physiological needs allowed. The blood samples were taken 3 minutes and 30 minutes after cessation of the exercise to measure the bLa. The Borg CR-10 Scale was presented to the participants 3 minutes and 30 minutes after cessation of the exercise to measure the rate of perceived exertion (RPE) (Borg, 1998).

Condition or disease Intervention/treatment Phase
Blood Lactate Decrease Behavioral: Voluntary Isocapnic Hyperpnea Not Applicable

Detailed Description:

All the study participants performed the Wingate Anaerobic Test (WAnT) with maximal effort. The experimental group (E) performed a 3-minute recovery protocol based on low-intensity breathing VIH exercises 20 minuter after cessation of the exercise, whereas the control group (C) used passive recovery only. All study participants were advised to sit during the 30-minute period, with minimal walking in order to meet the physiological needs allowed. The blood samples were taken 3 minutes and 30 minutes after cessation of the exercise to measure the bLa. The Borg CR-10 Scale was presented to the participants 3 minutes and 30 minutes after cessation of the exercise to measure the rate of perceived exertion (RPE).

WAnT was conducted using a Monark 874E Cycle Ergometer (Monark Exercise AB, Sweden). Prior to the test, a standard warm-up of 5 minutes was performed with a load of 0.8-1.2 W/kg. Then, athletes performed a maximal 6-second sprint with a load adjusted to 7.5% of the individual body weight. Following a 2-minute rest period, the athletes underwent a 30-second WAnT with the load adjusted to 7.5% of the individual body weight. The objective for the subjects was to achieve the highest possible peak power as fast as possible and maintain the highest power output throughout the whole test duration. Loud and dynamic verbal encouragement was provided. The testing took place between 9:00 and 10:30 AM. The basic mechanical parameters of the exercise, including performed work and maximum power, were computed with dedicated software (MCE 6.0 - JBA Z. Staniak, Poland) linked to the cycle ergometer.

The recovery protocol consisted of 3' of breathing with 20 breaths·min-1 frequency. The Isocapnic BreathWayBetter devices (Isocapnic Technologies Inc, Kelowna, Canada) with 6-liter bags were used. The protocol was performed in a seating position.

Blood samples were taken from fingertips by skilled technicians to 20 uL capillary tubes. bLa was measured with Super GL2 analyzer (Dr. Müller Gerätebau GmbH, Freital, Germany).

Whereas participants and data collectors were aware of the allocated training method, the laboratory technicians performing biochemistry assays were kept blinded to the allocation. The participants were assigned at random to either E or C group to perform VIH protocol under a supervision of qualified physiotherapist.

Stratified randomization to assign the participants was used. First, the participants were assigned to subgroups based on the membership in National Development or National Elite Team. Then, the participants were assigned to subgroups based on the gender. Then, the participants were assigned to E or C group based on the coin toss.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel Group Randomized Controlled Trial
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Influence of Voluntary Isocapnic Hyperpnea on Blood Lactate Level and Rate of Perceived Exertion
Actual Study Start Date : June 10, 2023
Actual Primary Completion Date : July 30, 2023
Actual Study Completion Date : July 30, 2023
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Experimental Behavioral: Voluntary Isocapnic Hyperpnea
The protocol of 3' of breathing with 20 breaths·min-1 frequency. The Isocapnic BreathWayBetter devices (Isocapnic Technologies Inc, Kelowna, Canada) with 6-liter bags were used. The protocol was performed in a seating position.
No Intervention: Control


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Changes in blood lactate (bLa) [ Time Frame: 30 minutes ]

    The blood samples were taken 3 minutes and 30 minutes after cessation of the exercise to measure the bLa.

    Blood samples were taken from fingertips by skilled technicians to 20 uL capillary tubes. bLa was measured with Super GL2 analyzer (Dr. Müller Gerätebau GmbH, Freital, Germany).


  2. Changes in rate of perceived exertion (RPE) [ Time Frame: 30 minutes ]
    The Borg CR-10 Scale was presented to the participants 3 minutes and 30 minutes after cessation of the exercise to measure the rate of perceived exertion (RPE) (Borg, 1998).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

The inclusion criteria:

  • valid medical certificate to compete in speedskating,
  • lack of previous experience with RMT,
  • at least 6 years of athletic training.

The exclusion criteria:

  • any chronic medical condition,
  • any acute medical condition within last 3 months,
  • any ongoing medication intake.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05994092


Locations
Layout table for location information
Poland
Institute of Sport - National Research Institute
Warsaw, Poland, 01-982
Sponsors and Collaborators
Institute of Sport - National Research Institute, Poland
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Tomasz Kowalski, Principal Investigator, Institute of Sport - National Research Institute, Poland
ClinicalTrials.gov Identifier: NCT05994092    
Other Study ID Numbers: TK03/2023
First Posted: August 16, 2023    Key Record Dates
Last Update Posted: August 18, 2023
Last Verified: August 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Upon reasonable request.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Tomasz Kowalski, Institute of Sport - National Research Institute, Poland:
Voluntary Isocapnic Hyperpnea
Lactate Clearance